Smoking habits in multiple system atrophy and progressive supranuclear palsy

被引:56
作者
Vanacore, N
Bonifati, V
Fabbrini, G
Colosimo, C
Marconi, R
Nicholl, D
Bonuccelli, U
Stocchi, F
Lamberti, P
Volpe, G
De Michele, G
Iavarone, I
Bennett, P
Vieregge, P
Meco, G
机构
[1] Univ La Sapienza, Dept Neurosci, I-00185 Rome, Italy
[2] Misericordia Hosp, Neurol Serv, Grosseto, Italy
[3] Univ Birmingham, Dept Clin Neurol, Birmingham, W Midlands, England
[4] Univ Pisa, Inst Neurol, I-56100 Pisa, Italy
[5] Univ Bari, Inst Neurol, I-70121 Bari, Italy
[6] Univ Naples Federico II, Dept Neurol Sci, Naples, Italy
[7] Natl Inst Hlth, Lab Environm Hyg, Rome, Italy
[8] Univ Birmingham, Dept Psychiat, Birmingham, W Midlands, England
[9] Med Univ Lubeck, Dept Neurol, Lubeck, Germany
关键词
multiple system atrophy; progressive supranuclear palsy; smoking;
D O I
10.1212/WNL.54.1.114
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To evaluate smoking habits in patients with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) in a multicenter case-control study to determine whether these two forms of atypical parkinsonism share the inverse association with smoking previously found in PD. Background: No epidemiologic studies have been performed on smoking habits in MSA. A previous investigation in PSP revealed no differences in smoking habits between patients and hospital control subjects. Methods: Seventy-six MSA patients, 55 PSP patients, 140 PD patients, and 134 healthy control subjects were enrolled consecutively at seven neurologic clinics from January 1, 1994, to July 31, 1998. Detailed information on smoking habits was obtained using a structured questionnaire. Results: The comparison between frequencies of never-smokers versus ever-smokers (ex-smokers/current smokers; adjusted odds ratio [ORadj], 0.56; 95% CI, 0.29 to 1.06) and a dose-response analysis for never-smokers, moderate smokers (ORadj, 0.64; 95% CI, 0.31 to 1.32), and heavy smokers (ORadj, 0.47; 95% CI, 0.21 to 1.05) suggest that MSA patients smoke less than population control subjects. By contrast, the comparison of frequencies of never-smokers versus ever-smokers (ORadj, 0.91; 95% CI, 0.42 to 1.98) and a dose-response analysis for never-smokers, moderate smokers (ORadj, 0.68; 95% CI, 0.21 to 1.69), and heavy smokers (ORadj, 1.24; CI 95%, 0.51 to 3.06) revealed no differences in smoking habits between PSP patients and population control subjects. Conclusions: The fact that the inverse association with smoking found previously in PD is shared by multiple system atrophy but not by progressive supranuclear palsy lends epidemiologic support to the notion that different smoking habits are associated with different groups of neurodegenerative disease.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 36 条
[1]   Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders [J].
Balfour, DJK ;
Fagerstrom, KO .
PHARMACOLOGY & THERAPEUTICS, 1996, 72 (01) :51-81
[2]   Cause of death in Alzheimer's disease [J].
Beard, CM ;
Kokmen, E ;
Sigler, C ;
Smith, GE ;
Petterson, T ;
OBrien, PC .
ANNALS OF EPIDEMIOLOGY, 1996, 6 (03) :195-200
[3]   Direct genetic evidence for involvement of tau in progressive supranuclear palsy [J].
Bennett, P ;
Bonifati, V ;
Bonuccelli, U ;
Colosimo, C ;
De Mari, M ;
Fabbrini, G ;
Marconi, R ;
Meco, G ;
Nicholl, DJ ;
Stocchi, F ;
Vanacore, N ;
Vieregge, P ;
Williams, AC .
NEUROLOGY, 1998, 51 (04) :982-985
[4]   Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990 [J].
Bower, JH ;
Maraganore, DM ;
McDonnell, K ;
Rocca, WA .
NEUROLOGY, 1997, 49 (05) :1284-1288
[5]   A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease [J].
Checkoway, H ;
Franklin, GM ;
Costa-Mallen, P ;
Smith-Weller, T ;
Dilley, J ;
Swanson, PD ;
Costa, LG .
NEUROLOGY, 1998, 50 (05) :1458-1461
[6]   POOR METABOLIZERS OF NICOTINE AND CYP2D6 POLYMORPHISM [J].
CHOLERTON, S ;
ARPANAHI, A ;
MCCRACKEN, N ;
BOUSTEAD, C ;
TABER, H ;
JOHNSTONE, E ;
LEATHART, J ;
DALY, AK ;
IDLE, JR .
LANCET, 1994, 343 (8888) :62-63
[7]  
Clayton D., 1993, STAT MODELS EPIDEMIO
[8]   The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease [J].
Clayton, DF ;
George, JM .
TRENDS IN NEUROSCIENCES, 1998, 21 (06) :249-254
[9]   THE SHORT-TERM EFFECT OF NICOTINE CHEWING GUM IN PATIENTS WITH PARKINSONS-DISEASE [J].
CLEMENS, P ;
BARON, JA ;
COFFEY, D ;
REEVES, A .
PSYCHOPHARMACOLOGY, 1995, 117 (02) :253-256
[10]   Genetic evidence for the involvement of tau in progressive supranuclear palsy [J].
Conrad, C ;
Andreadis, A ;
Trojanowski, JQ ;
Dickson, DW ;
Kang, D ;
Chen, XH ;
Wiederholt, W ;
Hansen, L ;
Masliah, E ;
Thal, LJ ;
Katzman, R ;
Xia, Y ;
Saitoh, T .
ANNALS OF NEUROLOGY, 1997, 41 (02) :277-281